Oncology News and Research

RSS

Oncology, meaning bulk, mass, or tumor, and the suffix ''-logy'', meaning "study of") is a branch of medicine that deals with tumors (cancer). A medical professional who practices oncology is an ''oncologist''.

Brentuximab vedotin-chemotherapy combination clinical trial for Hodgkin lymphoma announced

Seattle Genetics, Inc. and Millennium Pharmaceuticals, Inc.: The Takeda Oncology Company today announced that they have initiated a phase I clinical trial of brentuximab vedotin (SGN-35) in combination with chemotherapy for the treatment of newly diagnosed Hodgkin lymphoma patients. Brentuximab vedotin is an antibody-drug conjugate (ADC) that is also in single-agent clinical trials, including a pivotal trial for relapsed and refractory Hodgkin lymphoma and a phase II trial for systemic anaplastic large cell lymphoma.

4 Feb 2010

Prolactin reduces the levels of BCL6 protein and prevents aggressive breast cancer

Researchers from the Kimmel Cancer Center at Jefferson have found a mechanism by which a hormone responsible for milk production blocks an oncogene that makes breast cancer more aggressive.

4 Feb 2010

Inverness Medical Innovations to acquire Kroll's Substance Abuse Testing division

Inverness Medical Innovations, Inc., a global leader in enabling individuals to take charge of their health at home through the merger of rapid diagnostics and health management, announced today that it has entered into a binding agreement with Kroll Inc., a subsidiary of Marsh and McLennan Companies, Inc. to purchase its Substance Abuse Testing division (Kroll Laboratory Specialists, Inc.), its business unit providing forensic quality substance abuse testing products and services across the United States.

4 Feb 2010

Validation results of SmartChip Real-Time PCR System to be presented at CHI's conference

WaferGen Biosystems, Inc., a leading developer of state-of-the-art genetic analysis systems, today announced that WaferGen scientists will present validation results of the company's SmartChip™ Real-Time PCR System at Cambridge Healthcare Institute's 17th International Molecular Medicine Tri-Conference.

3 Feb 2010

Keryx Biopharmaceuticals reaches agreement with FDA on SPA for Phase 3 trial of KRX-0401

Keryx Biopharmaceuticals, Inc. announced today that it has reached agreement with the U.S. Food and Drug Administration (FDA) regarding a Special Protocol Assessment (SPA) on the design of a Phase 3 trial for its PI3K/Akt pathway inhibitor, KRX-0401 (perifosine), in patients with refractory metastatic colorectal cancer.

3 Feb 2010

MPR drug information now available for iPhone and iPod touch

MPR – the most widely used drug reference by clinicians – is now available as a free App for the iPhone and iPod touch. The MPR drug database is also available for free for BlackBerry, Palm, and Microsoft Mobile devices, as well as desktop and laptop computers running Microsoft XP and Microsoft Vista (www.empr.com/download).

3 Feb 2010

TGen, Horizon Discovery partner in development of novel cancer cell-lines

The Translational Genomics Research Institute (TGen) and Horizon Discovery today announced plans to develop human disease models for use in TGen's cancer research.

3 Feb 2010

Study indicates majority of physicians are not following DSM-IV guidelines for major depressive disorder

A new study led by Mark Zimmerman, MD, of Rhode Island Hospital indicates that a majority of non-psychiatrist physicians and a substantial minority of psychiatrists reported that they often do not use the criteria outlined in the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) when diagnosing major depressive disorder (MDD) in patients. The study appears online ahead of print in the Journal of Clinical Psychiatry.

3 Feb 2010

News article on the evolving role of hyperthermia in cancer therapy

BSD Medical Corp. reports publication of a news article by the Journal of the National Cancer Institute on the evolving role of hyperthermia in cancer therapy titled, “International Study of Hyperthermia Spurs Hope in U.S.” (J. Natl. Cancer Inst. 2010 102: 79-81; doi:10.1093/jnci/djp530).

3 Feb 2010

Dayton Physicians select IntrinsiQ’s chemotherapy management system for improving patient care

Dayton Physicians LLC, one of Ohio’s leading multi-specialty cancer treatment centers, has selected IntrinsiQ’s IntelliDose® clinical software to manage complex chemotherapy treatment, safely and efficiently.

3 Feb 2010

Veran Medical Technologies receives two FDA clearances to expand the use of ig4 Navigation platform

Veran Medical Technologies announced today that it has recently received two clearances (K093146 & K093995) from the U.S. Food and Drug Administration (FDA) to expand its indications for use of the ig4 Navigation platform.

3 Feb 2010

Study could provide potential therapeutic strategies for treating prostate cancer

Prostate cancer cells are more likely to spread to other parts of the body if a specific gene quits functioning normally, according to new data from researchers at UT Southwestern Medical Center.

3 Feb 2010

EpiCept regains compliance with Nasdaq minimum bid price requirement

EpiCept Corporation today announced that Nasdaq notified the Company that it has regained compliance with the minimum bid price requirement in Listing Rule 5550(a)(2) and met the requirements of the Nasdaq Listing Qualification Panel (the “Panel”) decision dated November 2, 2009. Accordingly, the Panel has determined to continue the listing of the Company’s common stock on The Nasdaq Stock Market.

3 Feb 2010

VIDAZA prolongs survival in AML patients

The Myelodysplastic Syndromes (MDS) Foundation says a study published this week in the Journal of Clinical Oncology concludes VIDAZA (azacitidine) “prolongs survival and is well tolerated” in patients with acute myeloid leukemia (AML) - an aggressive form of leukemia that in many cases progresses from MDS.

3 Feb 2010

GenSpera’s G-115 anti-cancer drug awarded US patent

GenSpera, Inc. announced that its patent application, entitled “Tumor Activated Prodrugs,” has been issued by the United States Patent and Trademark Office (USPTO) as US Patent 7,635,682. The patent covers the composition and potential uses of G-115, GenSpera’s second anti-cancer drug in development.

2 Feb 2010

Gentag signs license agreement to develop and commercialize post surgery wireless skin patch

Gentag, Inc. and The CORE Institute® are pleased to announce the signing of a license agreement to develop and commercialize a disposable wireless skin patch to allow patients to self monitor themselves in the comfort of their homes after orthopedic surgery in hospitals through the use of cell phones

2 Feb 2010

Vantia Therapeutics initiates Phase IIb trial of VA106483 for nocturia

Vantia Therapeutics, an emerging pharmaceutical company developing novel, small molecule drugs targeting large, underserved medical markets, today announces it has begun its planned Phase IIb trial of its lead development compound VA106483 for nocturia.

2 Feb 2010

RECOTHROM topical hemostat exhibits low rate of anti-product antibody formation

ZymoGenetics, Inc., today announced the publication of pooled safety and immunogenicity observations from eight clinical trials of RECOTHROM in the February issue of the Journal of the American College of Surgeons. The authors concluded that RECOTHROM is a well-tolerated topical hemostatic agent in numerous surgical settings and has a low rate of anti-product antibody formation. In the pooled data from all trials, less than one percent of treated patients developed product-specific antibodies. None of the antibodies neutralized native coagulation proteins.

2 Feb 2010

Cytheris broadens patent protection for recombinant human interleukin-7

Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for its patent application "Glycosylated IL-7, Preparation and Uses", US Patent Application Number 11/996,176. The Notice of Allowance is the USPTO’s official communication that the Company’s application has successfully completed examination and that a patent will be issued.

2 Feb 2010

Spectrum Pharmaceuticals signs co-development and commercialization agreement with TopoTarget A/S

Spectrum Pharmaceuticals, a commercial-stage biotechnology company with a primary focus in oncology, today announced that it has entered into a co-development and commercialization agreement with TopoTarget A/S for Belinostat, a novel histone deacetylase (HDAC) inhibitor.

2 Feb 2010

Oncology News and Research

Further Reading

Brentuximab vedotin-chemotherapy combination clinical trial for Hodgkin lymphoma announced

Prolactin reduces the levels of BCL6 protein and prevents aggressive breast cancer

Inverness Medical Innovations to acquire Kroll's Substance Abuse Testing division

Validation results of SmartChip Real-Time PCR System to be presented at CHI's conference

Keryx Biopharmaceuticals reaches agreement with FDA on SPA for Phase 3 trial of KRX-0401

MPR drug information now available for iPhone and iPod touch

TGen, Horizon Discovery partner in development of novel cancer cell-lines

Study indicates majority of physicians are not following DSM-IV guidelines for major depressive disorder

News article on the evolving role of hyperthermia in cancer therapy

Dayton Physicians select IntrinsiQ’s chemotherapy management system for improving patient care

Veran Medical Technologies receives two FDA clearances to expand the use of ig4 Navigation platform

Study could provide potential therapeutic strategies for treating prostate cancer

EpiCept regains compliance with Nasdaq minimum bid price requirement

VIDAZA prolongs survival in AML patients

GenSpera’s G-115 anti-cancer drug awarded US patent

Gentag signs license agreement to develop and commercialize post surgery wireless skin patch

Vantia Therapeutics initiates Phase IIb trial of VA106483 for nocturia

RECOTHROM topical hemostat exhibits low rate of anti-product antibody formation

Cytheris broadens patent protection for recombinant human interleukin-7

Spectrum Pharmaceuticals signs co-development and commercialization agreement with TopoTarget A/S

Cancer Research eBook

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News